Evidence map›Paper›PMID 36261831›Full record

ReviewMolecular cancer2022

Tumor buster - where will the CAR-T cell therapy 'missile' go?

Chunrun Qu, Hao Zhang, Hui Cao, Lanhua Tang, Haoyang Mo, Fangkun Liu, Liyang Zhang, Zhenjie Yi, Lifu Long, Luzhe Yan and 8 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Drug delivery for age-related bone diseases: From therapeutic targets to common and emerging therapeutic strategies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Chunrun Qu *Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hao Zhang *Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hui CaoDepartment of Psychiatry, The Second People's Hospital of Hunan Province, The Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
Lanhua TangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Haoyang MoDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Fangkun LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Liyang ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhenjie YiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Lifu LongDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Luzhe YanXiangYa School of Medicine, Central South University, Changsha, Hunan, China.
Zeyu WangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Nan ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Peng LuoDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Jian ZhangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Zaoqu LiuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou, Zhengzhou, Henan, China.
Weijie YeDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhixiong LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. zhixiongliu@csu.edu.cn.
Quan ChengDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. chengquan@csu.edu.cn.ORCID 0000-0003-2401-5349
Central South University · CNZhujiang Hospital · CNHunan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic modification to enable T cells to target tumor-specific antigens, attack specific cancer cells, and bypass tumor cell apoptosis avoidance mechanisms to some extent. This method has been extensively used to treat hematologic diseases, but the therapeutic effect in solid tumors is not ideal. Tumor antigen escape, treatment-related toxicity, and the immunosuppressive tumor microenvironment (TME) limit their use of it. Target selection is the most critical aspect in determining the prognosis of patients receiving this treatment. This review provides a comprehensive summary of all therapeutic targets used in the clinic or shown promising potential. We summarize CAR-T cell therapies' clinical trials, applications, research frontiers, and limitations in treating different cancers. We also explore coping strategies when encountering sub-optimal tumor-associated antigens (TAA) or TAA loss. Moreover, the importance of CAR-T cell therapy in cancer immunotherapy is emphasized.

Indexed as

NeoplasmsReceptors, Chimeric AntigenAntigens, NeoplasmCell- and Tissue-Based TherapyHumansImmunotherapy, AdoptiveTumor MicroenvironmentAntigens, NeoplasmReceptors, Chimeric AntigenCancerCAR-T cellImmunotherapyPersonalized treatmentTarget

Identifiers

PMID36261831
PMCPMC9580202
OpenAlexW4306773867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.